What is Inflammatory bowel disease?
Inflammatory
bowel disease (IBD), a chronic immune inflammatory response within the
alimentary canal, is assessed as 2 major forms, Crohn’s disease (CD) and
colitis (UC). A rise within the frequency of IBD (from 68.6 cases per 100,000
people in 1990 to 89.6 cases per 100,000 people in 2017) in developing
countries has become a big ill health over the last three decades]. Usually,
IBD causes symptoms like fatigue, diarrhoea, and abdominal pain. The
pathogenesis of IBD remains not fully understood but appears to be influenced
by interplay between genetic factors, environmental factors, immunological
factors, and disruption of the intestinal microbiota composition. Current treatment
options for IBD are mainly supported conventional methods like treatment with
5-aminosalicylic acid, corticosteroids, and immunosuppressive drugs; however,
these therapies generally cause significant side effects and a large subset of
patient relapse.
The intestine
is that the largest digestive organ within the physical body and plays a
central role in human defence. CD4+ T cells, which are a crucial cell
population within the colonic lamina propria and epithelium, are vital for the
upkeep of intestinal immune homeostasis. CD4+ T cells are divided into
subgroups: T helper (Th) 1, Th2, Th17, and regulatory T (Treg) cells. During
the inflammatory process, Th1 cells can generate tumour necrosis factor- (TNF-)
α and interferon- (IFN-) γ. Th2 cells produce interleukin- (IL-) 10, which is
critical for cover against pathogens. Th17 cells also are involved within the
pathogenesis of IBD through the secretion of IL-17A, IL-17F, and IL-22.
Additionally, Treg cells have also been reported to inhibit inflammatory reactions
and relieve the event of IBD by secreting immunosuppressive factors like IL-10.
Many studies have reported that the gut microbiota
affects normal physiological and biochemical functions and is related to a
spread of diseases, like disease, cancer, and particularly IBD. During a study
on IBD, the composition and performance of the gut microbiota of patients with
IBD were found to be modified, which can end in the impairment of gut
physiological function. A decrease in beneficial bacteria, like Bifid bacterium, was
found in patients with IBD. Generally, modulation of the gut microbiota is
predicted to become a crucial treatment method for IBD.
Comments
Post a Comment